Experimental CRP-targeting strategies have been suggested and investigated in numerous indications, including cardiovascular incidents (AMI, ischemic stroke), hyperinflammatory settings (COVID-19, pancreatitis) and autoimmune diseases (rheumathoid arthritis [112], Crohn’s disease [10]). The gene discussed is CRP; the disease is Crohn disease.